Clinical decision making in the treatment of mania.
Nine agents are now Food and Drug Administration-approved for acute treatment of bipolar mania, and several other agents are being studied for efficacy. With multiple treatment options available, clinicians face the challenge of selecting among agents. Although clinicians may consult the American Psychiatric Association's Practice Guideline for the Treatment of Patients With Bipolar Disorder, Second Edition, when selecting a treatment for bipolar mania, decisions about many aspects of treatment, such as choosing among agents, comparing combination therapy versus monotherapy, and individualizing treatments, remain complex. Considering data from recent clinical studies that have compared the efficacy, safety, and tolerability of medications for bipolar mania both between and within classes may facilitate such treatment decisions.
Perlis
Roy H
RH
Department of Psychiatry, Harvard Medical School, and Bipolar Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA. rperlis@partners.org
D016907:Adverse Drug Reaction Reporting Systems; D018692:Antimanic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003661:Decision Support Techniques; D004359:Drug Therapy, Combination; D006801:Humans; D016651:Lithium Carbonate / Q000009:adverse effects / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D016651:Lithium Carbonate; D014635:Valproic Acid